SOPHiA GENETICS (NASDAQ:SOPH – Get Rating) and Allena Pharmaceuticals (NASDAQ:ALNAQ – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.
Valuation & Earnings
This table compares SOPHiA GENETICS and Allena Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.
Get
SOPHiA GENETICS alerts:
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| SOPHiA GENETICS | $40.45 million | 4.06 | -$73.68 million | ($1.48) | -1.75 |
| Allena Pharmaceuticals | N/A | N/A | -$48.66 million | N/A | N/A |
Allena Pharmaceuticals has lower revenue, but higher earnings than SOPHiA GENETICS.
Volatility and Risk
SOPHiA GENETICS has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Allena Pharmaceuticals has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations and price targets for SOPHiA GENETICS and Allena Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| SOPHiA GENETICS | 0 | 1 | 1 | 0 | 2.50 |
| Allena Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
SOPHiA GENETICS currently has a consensus target price of $7.00, suggesting a potential upside of 170.27%. Given SOPHiA GENETICS's higher possible upside, research analysts clearly believe SOPHiA GENETICS is more favorable than Allena Pharmaceuticals.
Profitability
This table compares SOPHiA GENETICS and Allena Pharmaceuticals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
| SOPHiA GENETICS | -210.25% | -39.47% | -33.12% |
| Allena Pharmaceuticals | N/A | -287.46% | -146.58% |
Insider and Institutional Ownership
31.0% of SOPHiA GENETICS shares are owned by institutional investors. Comparatively, 0.2% of Allena Pharmaceuticals shares are owned by institutional investors. 3.7% of Allena Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
SOPHiA GENETICS beats Allena Pharmaceuticals on 6 of the 10 factors compared between the two stocks.
About SOPHiA GENETICS
(Get Rating)
SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.
About Allena Pharmaceuticals
(Get Rating)
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. On September 2, 2022, Allena Pharmaceuticals, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
